Cargando…

BET bromodomain proteins are required for glioblastoma cell proliferation

Epigenetic proteins have recently emerged as novel anticancer targets. Among these, bromodomain and extra terminal domain (BET) proteins recognize lysine-acetylated histones, thereby regulating gene expression. Newly described small molecules that inhibit BET proteins BRD2, BRD3, and BRD4 reduce pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pastori, Chiara, Daniel, Mark, Penas, Clara, Volmar, Claude-Henry, Johnstone, Andrea L, Brothers, Shaun P, Graham, Regina M, Allen, Bryce, Sarkaria, Jann N, Komotar, Ricardo J, Wahlestedt, Claes, Ayad, Nagi G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121371/ https://www.ncbi.nlm.nih.gov/pubmed/24496381 http://dx.doi.org/10.4161/epi.27906

Ejemplares similares

Epigenetic pathways and glioblastoma treatment
por: Clarke, Jennifer, et al.
Publicado: (2013)

Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme
por: Tan, Sze Kiat, et al.
Publicado: (2018)

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion
por: Jermakowicz, Anna M., et al.
Publicado: (2021)

The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer’s Disease
por: Magistri, Marco, et al.
Publicado: (2016)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

Drug and disease signature integration identifies synergistic combinations in glioblastoma
por: Stathias, Vasileios, et al.
Publicado: (2018)

Emerging treatment strategies for glioblastoma multiforme
por: Carlsson, Steven K, et al.
Publicado: (2014)

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT
por: Copsel, Sabrina N., et al.
Publicado: (2019)

Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL (TM))
por: Kemper, Christopher, et al.
Publicado: (2022)

Identifying Glioblastoma Gene Networks Based on Hypergeometric Test Analysis
por: Stathias, Vasileios, et al.
Publicado: (2014)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients
por: Dennison, Jessica L., et al.
Publicado: (2022)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma
por: Lohse, Ines, et al.
Publicado: (2018)

Therapeutic potential of neuropeptide Y (NPY) receptor ligands
por: Brothers, Shaun P, et al.
Publicado: (2010)

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation
por: Colardo, Mayra, et al.
Publicado: (2023)

Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy
por: Gargano, Deborah, et al.
Publicado: (2023)

Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model
por: Janczura, Karolina J., et al.
Publicado: (2018)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

HDAC Inhibitors Induce BDNF Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons
por: Bagheri, Amir, et al.
Publicado: (2019)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor
por: Dutra, Luiz Antonio, et al.
Publicado: (2017)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Nucleic acid-based therapeutics for the treatment of central nervous system disorders
por: McCartan, Robyn, et al.
Publicado: (2023)

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
por: Fu, Lei-lei, et al.
Publicado: (2015)

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
por: Wang, Bowen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nlu4inbfd3ceb5lcble1lus1n8